Precision cancer therapy works in 3/4 of patients: study
A precision cancer treatment that targets rare genetic mutations that exist in about 5,000 people in the United States instead of the tumor’s location in the body has shown success in three-quarters of patients, researchers said Wednesday. The medicine, called larotrectinib, is made by Loxo Oncology of Stamford, Connecticut and was granted breakthrough therapy designation by…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “Precision cancer therapy works in 3/4 of patients: study”
Sure is empty down here...